InflaRx N.V. (IFRX)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $172.42M
Last updated: Nov 17, 2026 at 11:06 AM ET
InflaRx N.V. (IFRX) Competitors
The companies most similar to InflaRx are Innate Pharma (IPHA), Inhibikase Therapeutics (IKT) and Immuneering (IMRX). By market cap, InflaRx ranks 6th of the 13 companies on this page; Inovio Pharmaceuticals (INO) is the largest at $267.85M.
Peer Comparison
IFRX's revenue growth of -80.8% is below the peer median of 4.6%. Like the median peer, it pays no dividend.
| Company | Market cap | P/E | P/S | Net margin | ROIC | Rev growth | Div yield |
|---|---|---|---|---|---|---|---|
| InflaRx (IFRX) | $172.42M | N/A | N/A | 0.0% | N/A | -80.8% | 0.00% |
| Innate Pharma (IPHA) | $154.15M | N/A | 17.6x | 0.0% | 489.8% | 16.5% | 0.00% |
| Inhibikase Therapeutics Inc (IKT) | $213.21M | N/A | N/A | 0.0% | N/A | -100.0% | 0.00% |
| Immuneering Corp (IMRX) | $240.27M | N/A | N/A | 0.0% | N/A | -99.8% | 0.00% |
| Invivyd Inc. (IVVD) | $171.58M | N/A | 2.9x | -183.9% | N/A | 21.2% | 0.00% |
| Inovio Pharmaceuticals Inc (INO) | $267.85M | N/A | 462.0x | 0.0% | N/A | -100.0% | 0.00% |
| NRX Pharmaceuticals Inc (NRXP) | $95.58M | N/A | 23.8x | 0.0% | N/A | 0.0% | 0.00% |
| ProQR Therapeutics BV (PRQR) | $199.28M | N/A | 6.1x | -228.2% | N/A | 120.4% | 0.00% |
| Fate Therapeutics Inc (FATE) | $155.74M | N/A | 29.7x | 0.0% | -51.3% | 9.2% | 0.00% |
| Upstream Bio, Inc. (UPB) | $152.38M | N/A | 41.0x | 0.0% | N/A | -42.2% | 0.00% |
| Immunic Inc (IMUX) | $102.61M | N/A | N/A | 0.0% | N/A | 0.0% | 0.00% |
| Armata Pharmaceuticals Inc (ARMP) | $143.94M | N/A | 14.7x | 0.0% | -184.6% | 173.6% | 0.00% |
| Protalix Biotherapeutics Inc (PLX) | $257.17M | 12.1x | 2.9x | 24.3% | N/A | 22.8% | 0.00% |
| Peer median | $163.66M | 12.1x | 17.6x | 0.0% | -51.3% | 4.6% | 0.00% |
Similar Companies
These are the 12 companies most similar to InflaRx, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.
| Company | About | Peers |
|---|---|---|
| Innate Pharma (IPHA) | Innate Pharma SA, a biotechnology company, discovers, develops and markets therapeutic antibodies for the treatment of oncological indications in France... | |
| Inhibikase Therapeutics Inc (IKT) | Inhibikase Therapeutics, Inc., a clinical-stage pharmaceutical company, develops therapies for Parkinson's disease (PD) and related disorders that arise inside... | IKT competitors |
| Immuneering Corp (IMRX) | Immuneering Corp (IMRX) is a cutting-edge biotechnology firm dedicated to advancing targeted therapeutics for cancer and other critical illnesses through its... | IMRX competitors |
| Invivyd Inc. (IVVD) | Adagio Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on the discovery... | IVVD competitors |
| Inovio Pharmaceuticals Inc (INO) | Inovio Pharmaceuticals, Inc., a biotechnology company, focuses on the discovery, development... | INO competitors |
| NRX Pharmaceuticals Inc (NRXP) | NRx Pharmaceuticals, Inc., a clinical-stage small molecule pharmaceutical company... | NRXP competitors |
| ProQR Therapeutics BV (PRQR) | ProQR Therapeutics NV, a biopharmaceutical company, is dedicated to the discovery and development of RNA-based therapies for the treatment of genetic disorders. | PRQR competitors |
| Fate Therapeutics Inc (FATE) | Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders globally. | FATE competitors |
| Upstream Bio, Inc. (UPB) | Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases that focuses on severe respiratory disorders. | UPB competitors |
| Immunic Inc (IMUX) | Immunic, Inc., a clinical-stage biopharmaceutical company, develops a line of selective oral immunology therapies for the treatment of chronic autoimmune... | IMUX competitors |
| Armata Pharmaceuticals Inc (ARMP) | Armata Pharmaceuticals Inc., a clinical-stage biotechnology company, focuses on the development of specific bacteriophage therapies for the treatment... | ARMP competitors |
| Protalix Biotherapeutics Inc (PLX) | Protalix BioTherapeutics, Inc., a biopharmaceutical company, focuses on the development and commercialization of recombinant therapeutic proteins based on its... | PLX competitors |
Frequently Asked Questions About IFRX
Who are InflaRx's main competitors?
The companies most similar to InflaRx include Innate Pharma (IPHA), Inhibikase Therapeutics (IKT), Immuneering (IMRX), Invivyd (IVVD) and Inovio Pharmaceuticals (INO), listed from the closest match.
Who is InflaRx's biggest competitor?
Inovio Pharmaceuticals (INO) is the largest of the similar companies at $267.85M; Innate Pharma (IPHA) is the closest match by business profile, size, sector and industry.
How does IFRX stock compare with its competitors?
IFRX's net margin is 0.0% against a peer median of 0.0%.
Which of InflaRx's competitors pays a higher dividend?
InflaRx pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.
Is InflaRx bigger than its competitors?
No. InflaRx is 6th by market cap among the 13 companies on this page; the largest is Inovio Pharmaceuticals (INO) at $267.85M.
IFRX pages: Overview, Financials, Competitors